These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 17508773)
21. Revealing the mechanistic pathway of cholinergic inhibition of Alzheimer's disease by donepezil: a metadynamics simulation study. Ghosh S; Jana K; Ganguly B Phys Chem Chem Phys; 2019 Jul; 21(25):13578-13589. PubMed ID: 31173012 [TBL] [Abstract][Full Text] [Related]
22. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Samadi A; de los Ríos C; Bolea I; Chioua M; Iriepa I; Moraleda I; Bartolini M; Andrisano V; Gálvez E; Valderas C; Unzeta M; Marco-Contelles J Eur J Med Chem; 2012 Jun; 52():251-62. PubMed ID: 22503231 [TBL] [Abstract][Full Text] [Related]
23. Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs. Lazarevic-Pasti T; Leskovac A; Momic T; Petrovic S; Vasic V Curr Med Chem; 2017; 24(30):3283-3309. PubMed ID: 28685687 [TBL] [Abstract][Full Text] [Related]
24. Acetylcholinesterase inhibitors from plants. Mukherjee PK; Kumar V; Mal M; Houghton PJ Phytomedicine; 2007 Apr; 14(4):289-300. PubMed ID: 17346955 [TBL] [Abstract][Full Text] [Related]
25. Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. Mizutani MY; Itai A J Med Chem; 2004 Sep; 47(20):4818-28. PubMed ID: 15369385 [TBL] [Abstract][Full Text] [Related]
26. Anti-cholinergic alkaloids as potential therapeutic agents for Alzheimer's disease: an in silico approach. Naaz H; Singh S; Pandey VP; Singh P; Dwivedi UN Indian J Biochem Biophys; 2013 Apr; 50(2):120-5. PubMed ID: 23720886 [TBL] [Abstract][Full Text] [Related]
27. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A; Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702 [TBL] [Abstract][Full Text] [Related]
28. In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease. Hu XM; Dong W; Cui ZW; Gao CZ; Yu ZJ; Yuan Q; Min ZL J Mol Model; 2018 Jun; 24(7):151. PubMed ID: 29869722 [TBL] [Abstract][Full Text] [Related]
29. Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer's Disease-Diabetes Dual Therapy. Rizvi SM; Shaikh S; Naaz D; Shakil S; Ahmad A; Haneef M; Abuzenadah AM Neurochem Res; 2016 Jun; 41(6):1475-82. PubMed ID: 26886763 [TBL] [Abstract][Full Text] [Related]
30. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Duysen EG; Li B; Darvesh S; Lockridge O Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517 [TBL] [Abstract][Full Text] [Related]
31. Searching for the Multi-Target-Directed Ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H₃R and BACE 1 inhibitory activities. Huang W; Tang L; Shi Y; Huang S; Xu L; Sheng R; Wu P; Li J; Zhou N; Hu Y Bioorg Med Chem; 2011 Dec; 19(23):7158-67. PubMed ID: 22019465 [TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. Muñoz-Ruiz P; Rubio L; García-Palomero E; Dorronsoro I; del Monte-Millán M; Valenzuela R; Usán P; de Austria C; Bartolini M; Andrisano V; Bidon-Chanal A; Orozco M; Luque FJ; Medina M; Martínez A J Med Chem; 2005 Nov; 48(23):7223-33. PubMed ID: 16279781 [TBL] [Abstract][Full Text] [Related]
33. Cooperative hydrogen bonds and mobility of the non-aromatic ring as selectivity determinants for human acetylcholinesterase to similar anti-Alzheimer's galantaminics: a computational study. Rocha REO; Lima LHF J Biomol Struct Dyn; 2019 Apr; 37(7):1843-1856. PubMed ID: 29697300 [TBL] [Abstract][Full Text] [Related]
34. Synthesis and efficacy of 1-[bis(4-fluorophenyl)-methyl]piperazine derivatives for acetylcholinesterase inhibition, as a stimulant of central cholinergic neurotransmission in Alzheimer's disease. Sadashiva CT; Narendra Sharath Chandra JN; Ponnappa KC; Veerabasappa Gowda T; Rangappa KS Bioorg Med Chem Lett; 2006 Aug; 16(15):3932-6. PubMed ID: 16735118 [TBL] [Abstract][Full Text] [Related]
35. [Present trends in the development of drugs within the cholinesterase inhibitor group as therapeutic agents for Alzheimer's disease]. Patocka J; Fusek J Cesk Psychiatr; 1992 Sep; 88(5):258-69. PubMed ID: 1451205 [TBL] [Abstract][Full Text] [Related]
37. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Sugimoto H Chem Biol Interact; 2008 Sep; 175(1-3):204-8. PubMed ID: 18577377 [TBL] [Abstract][Full Text] [Related]
39. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Rees TM; Brimijoin S Drugs Today (Barc); 2003 Jan; 39(1):75-83. PubMed ID: 12669110 [TBL] [Abstract][Full Text] [Related]
40. Virtual Screening and Hit Selection of Natural Compounds as Acetylcholinesterase Inhibitors. Atanasova M; Dimitrov I; Ivanov S; Georgiev B; Berkov S; Zheleva-Dimitrova D; Doytchinova I Molecules; 2022 May; 27(10):. PubMed ID: 35630613 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]